Tamsulosin
As of the edition of 20 October 2026, Tamsulosin is a small molecule: marketed, first approved in 1995 (FR); acts on ADRA1A, ADRA1B and ADRA1D.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2011
- Kind
- Small molecule
- Brand name
- Flomax
- First approved
- 20 December 1995 (FR)
- Approvals on record
- 5 in 4 regions
- Holder of the most recent approval
- GSK; 4 holders in all
- Registered trials
- 146, 12 stopped early
- Disease areas
- Urinary and reproductive; Pregnancy and women's health; Mental health; Cancer; Nervous system; Infections
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
3 company-target rows on route B because of this drug.
Companies on route B for this drug
In the product3 company-target rows are on route B because of Tamsulosin.
See the 3 company-target rows on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 22 | 8 | 3 | 2 |
| Phase 1 | 42 | 36 | 5 | 0 |
| Phase 2 | 14 | 7 | 4 | 0 |
| Phase 3 | 29 | 18 | 2 | 5 |
| Phase 4 | 39 | 23 | 6 | 5 |
| All trials | 146 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Boehringer Ingelheim | Originator and Lead sponsor of trials | 1997 to now |
| GSK | Applicant and Lead sponsor of trials | 2003 to now |
| Sanofi | Acquired holder | 2019 to now |